Zonisamide Adjunctive Therapy in Intractable Childhood Epilepsy with Mitochondrial Respiratory Chain Complex Defects
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Zonisamide (ZNS) is a broad-spectrum antiepileptic drug (AED). Free radical scavenging is also a possible action mechanism of ZNS. As oxidative stress plays an important role in the pathogenesis of mitochondrial cytopathy, we studied the efficacy and safety of ZNS as possible long-term adjunctive therapy in intractable childhood epilepsy with mitochondrial respiratory chain complex (MRC) defects. Methods: MRC defects were confirmed by biochemical assays with muscle biopsies. We evaluated seizure frequencies and adverse effects in 38 childhood epilepsy patients with MRC defects who were maintained on ZNS for at least 12 months. Patients with more than 50% seizure reduction after 12 months were defined as responders. Results: As for clinical diagnosis of mitochondrial cytopathy, 13 cases (34.2%) were diagnosed as Leigh syndrome and the remaining 25 (65.8%) had uncategorized mitochondrial cytopathy with nonspecific encephalopathy. The response rates for each seizure type after 12 months of ZNS therapy ranged from 23.1 to 55.6%; partial seizures (55.6%; 10/18), absence seizures (50.0%; 2/4), tonic-clonic seizures (40.0%; 2/5), atonic seizures (36.4%; 4/11), spasms (33.3%; 2/6), tonic seizures (31.8%; 7/22) and myoclonic seizures (23.1%; 3/13). The response rate for epileptic syndromes such as West syndrome and Lennox-Gastaut syndrome after ZNS treatment are 33.3% and 55.6% respectively. Somnolence, irritability, anorexia and weight loss were noticed as adverse effects, but all were transient. Conclusion: ZNS could be an effective and safe candidate for adjunctive therapy in intractable childhood epilepsy with MRC defects. It could be considered preferentially for its free radical scavenging effect.
Abstract
Purpose: Zonisamide (ZNS) is a broad-spectrum antiepileptic drug (AED). Free radical scavenging is also a possible action mechanism of ZNS. As oxidative stress plays an important role in the pathogenesis of mitochondrial cytopathy, we studied the efficacy and safety of ZNS as possible long-term adjunctive therapy in intractable childhood epilepsy with mitochondrial respiratory chain complex (MRC) defects. Methods: MRC defects were confirmed by biochemical assays with muscle biopsies. We evaluated seizure frequencies and adverse effects in 38 childhood epilepsy patients with MRC defects who were maintained on ZNS for at least 12 months. Patients with more than 50% seizure reduction after 12 months were defined as responders. Results: As for clinical diagnosis of mitochondrial cytopathy, 13 cases (34.2%) were diagnosed as Leigh syndrome and the remaining 25 (65.8%) had uncategorized mitochondrial cytopathy with nonspecific encephalopathy. The response rates for each seizure type after 12 months of ZNS therapy ranged from 23.1 to 55.6%; partial seizures (55.6%; 10/18), absence seizures (50.0%; 2/4), tonic-clonic seizures (40.0%; 2/5), atonic seizures (36.4%; 4/11), spasms (33.3%; 2/6), tonic seizures (31.8%; 7/22) and myoclonic seizures (23.1%; 3/13). The response rate for epileptic syndromes such as West syndrome and Lennox-Gastaut syndrome after ZNS treatment are 33.3% and 55.6% respectively. Somnolence, irritability, anorexia and weight loss were noticed as adverse effects, but all were transient. Conclusion: ZNS could be an effective and safe candidate for adjunctive therapy in intractable childhood epilepsy with MRC defects. It could be considered preferentially for its free radical scavenging effect.
참고문헌 (28)
- Schmiedel J, "Mitochondrial cytopathies", J Neurol, 250, pp.267~277 (2003)
- Kunz WS., "The role of mitochondria in epileptogenesis", Curr Opin Neurol, 15, pp.179~184 (2002)
- Patel M, "Mitochondria dysfunction and oxidative stress : cause and consequence of epileptic seizures", Free Radic Biol Med, 37, pp.1951~1962 (2004)
- Kang HC, "Nonspecific mitochondrial disease with epilepsy in children : diagnostic approaches and epileptic phenotypes", Childs Nerv Syst, 23, pp.1301~1307 (2007)
- Lee YM, "Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions", Epilepsia, 49, pp.685~690 (2008)
- Cadenas E, "Production of superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beefheart mitochondria", Arch Biochem Biophys, 180, pp.248~257 (1977)
- Leppik IE., "Zonisamide: chemistry, mechanism of action, and pharmacokinetics", Seizure, 13(Suppl 1), pp.S5~S9 (2004)
- Sills G, "Pharmacokinetics and drug interactions with zonisamide", Epilepsia, 48, pp.435~441 (2007)
- Mori A, "The anticonvulsant zonisamide scavenges free radicals", Epilepsy Res, 30, pp.153~158 (1998)
- Noda Y, "Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus", Res Commun Mol Pathol Pharmacol, 105, pp.23~33 (1999)
- "Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures", Epilepsia, 22, pp.489~501 (1981)
- "Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes", Epilepsia, 30, pp.389~399 (1989)
- Berg AT, "Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009", Epilepsia, 51, pp.676~685 (2010)
- Kwan P, "Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies", Epilepsia, 51, pp.1069~1077 (2010)
- Rustin P, "Biochemical and molecular investigations in respiratory chain deficiencies", Clin Chim Acta, 228, pp.35~51 (1994)
- Chretien D, "Reference charts for respiratory chain activities in human tissues", Clin Chim Acta, 228, pp.53~70 (1994)
- Lee HF, "Epileptic seizures in infants and children with mitochondrial diseases", Pediatr Neurol, 45, pp.169~174 (2011)
- Glauser TA, "Zonisamide in pediatric epilepsy: review of the Japanese experience", J Child Neurol, 17, pp.87~96 (2002)
- Yagi K, "Methodological requirements for clinical trials in refractory epilepsies -our experience with zonisamide", Prog Neuropsychopharmacol Biol Psychiatry, 16, pp.79~85 (1992)
- Suzuki Y, "Zonisamide monotherapy in newly diagnosed infantile spasms", Epilepsia, 38, pp.1035~1038 (1997)
- Sakamoto K, "Therapeutic effects of zonisamide (AD-810) on infantile epilepsy", Med Consult New Remedies, 23, pp.2571~2581 (1986)
- Yamatogi Y, "New Trends in Pediatric Epileptology", pp.136~148 (1991), Okayama University Medical School
- Iinuma K, "Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multiinstitutional survey", Seizure, 13(Suppl 1), pp.S34~S39 (2004)
- Ohtahara S., "Zonisamide in the management of epilepsy-Japanese experience", Epilepsy Res, 68(Suppl 2), pp.S25~S33 (2006)
- You SJ, "Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience", Brain Dev, 30, pp.287~290 (2008)
- Kunz WS, "Mitochondrial complex I deficiency in the epileptic focus of patients with temporal lobe epilepsy", Ann Neurol, 48, pp.766~773 (2000)
- Liang LP, "Mitochondrial superoxide production in kainite-induced hippocampal damage", Neuroscience, 101, pp.563~570 (2000)
- Mattson RH, "The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps", Epilepsia, 37(Suppl 6), pp.S45~S53 (1996)